LGVN stock forecast, quote, news & analysis
Longeveron Inc is a clinical stage biotechnology company developing regenerative medicines to address unmet medical needs... Show more
Why Longeveron (LGVN) Stock Is Down 19% in the Last 30 Days
Key Takeaways
- Longeveron (LGVN) declined roughly 19% over the last 30 days, falling from about $2.48 to $2.01 per share.
- The slide extends a sharp selloff that followed the September ELPIS II Phase 2b topline readout, which missed its primary endpoint in hypoplastic left heart syndrome (HLHS).
- Management retained Lucid Capital Markets to explore strategic opportunities, signaling an ongoing review of the company's path forward.
- Updated ELPIS II data was selected for a Late-Breaking Science podium presentation at the American Heart Association 2026 Scientific Sessions.
- Over the last quarter, shares are down roughly 73%, reflecting the failed trial and continued investor de-risking.
- Investors should monitor upcoming quarterly results, further trial data updates, and Nasdaq minimum bid-price compliance.
- Explore additional pages for this ticker's Price Targets, Earnings, and Forecast to review more detailed analysis.
- For automated trading insights, explore Trending AI Robots.
Longeveron (LGVN) Company Overview and Market Position
Longeveron Inc. is a clinical-stage biotechnology company headquartered in Miami, Florida, focused on developing regenerative medicines for life-threatening and chronic aging-related conditions. Its lead investigational product, laromestrocel (LOMECEL-B), is an allogeneic mesenchymal stem cell (MSC) therapy isolated from the bone marrow of young, healthy adult donors. The company is advancing laromestrocel across three pipeline indications: hypoplastic left heart syndrome (HLHS), a rare and life-threatening pediatric heart condition; Alzheimer's disease; and pediatric dilated cardiomyopathy. The HLHS program holds Orphan Drug, Fast Track, and Rare Pediatric Disease designations from the U.S. Food and Drug Administration, while the Alzheimer's program has received Regenerative Medicine Advanced Therapy (RMAT) and Fast Track designations.
As a pre-revenue, clinical-stage developer, Longeveron's valuation is tied primarily to binary clinical data readouts and regulatory milestones rather than current earnings. Investors follow the stock closely because of the high-risk, high-reward profile of its lead program and the potential for transformative outcomes in underserved disease areas.
Longeveron (LGVN) Stock Price Performance: Last 30 Days vs. Quarter
Over the last 30 days, LGVN shares fell approximately 19%, declining from a close of about $2.48 to $2.01. The move was not linear: the stock traded as low as around $1.39 during the period before recovering, and it rose about 11% in a single session as updated trial news emerged. The overall trend, however, remained firmly downward.
The picture is starker over the last quarter. Three months ago, shares traded near $7.36; at roughly $2.01, the stock has declined about 73%. The overwhelming driver of that multi-month decline was the September clinical setback, which compressed a valuation that had been supported by optimism around the lead HLHS program.
What Drove LGVN Stock Price in the Last 30 Days
The 30-day decline reflects the market's continued reassessment of Longeveron following the failed ELPIS II trial, rather than a single new catalyst. Several developments shaped the move:
- Strategic review. On October 28, Longeveron announced it had retained Lucid Capital Markets as a financial advisor to explore potential strategic opportunities, including a possible business combination. The announcement signaled that management is evaluating options in the wake of the trial setback, a factor that added uncertainty around the stock's fundamental outlook.
- Updated trial data. On October 26, the company reported updated results from the ELPIS II Phase 2b study and noted that the data had been selected for a Late-Breaking Science podium presentation at the AHA 2026 Scientific Sessions. The update provided additional context but did not reverse the primary-endpoint miss.
- Earnings expectations. With third-quarter results approaching, investors weighed continued operating losses against a constrained cash position, contributing to persistent selling pressure.
- Compliance concerns. After the post-trial collapse pushed shares sharply lower, questions about Nasdaq minimum bid-price compliance and potential dilution from future financings weighed on sentiment.
Collectively, these factors kept the stock under pressure even as intraday volatility produced short-lived bounces.
What Drove LGVN Stock Performance Over the Last Quarter
The quarter's dominant event was the September 16 release of topline results from the ELPIS II Phase 2b trial evaluating laromestrocel in HLHS. The study did not meet its primary endpoint of improvement in right ventricular ejection fraction at month 12, prompting the company to announce it was exploring all options to maximize shareholder value. Shares plummeted roughly 55% to 60% in the immediate aftermath, erasing much of the optimism that had built around the program.
The setback compounded earlier pressure from a 1-for-10 reverse stock split completed in late August, which was implemented to help regain compliance with Nasdaq's minimum bid-price requirement. Although the company had previously secured up to $30 million in financing to fund operations into the fourth quarter of 2026, the failed trial refocused attention on the company's remaining pipeline optionality and its need to preserve capital. The result was a sustained, multi-month repricing of the stock.
Trending AI Robots
Tickeron's Trending AI Robots page showcases a curated selection of AI-driven trading bots from a broader platform offering hundreds of automated strategies across thousands of tickers. Only top-performing and most relevant bots appear in this section, with each bot varying in trading strategy, timeframe, and performance metrics. The page is designed to help traders and investors discover data-driven approaches and monitor automated signals alongside their own research. For those interested in how AI can complement traditional analysis, exploring the Trending AI Robots section can provide additional context on algorithmic trading tools.
LGVN Stock Forecast Drivers: What Investors Should Watch Next
Several factors are likely to influence LGVN over the coming months. Investors should monitor the company's quarterly earnings and cash-burn trajectory, as operating losses continue to pressure its balance sheet and may necessitate additional financing. The detailed ELPIS II data presentation at the AHA Scientific Sessions and any further analysis of exploratory endpoints could shape views on the program's remaining value. The outcome of the strategic review with Lucid Capital Markets is also pivotal, as any partnership, licensing agreement, or business combination would materially affect the company's path forward. Additionally, progress in the Alzheimer's disease and pediatric dilated cardiomyopathy programs, along with Nasdaq listing compliance and potential dilution from future share issuances, remain key risks. These are factual considerations for investors to evaluate, not predictions of future performance.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
LGVN in +56.91% Uptrend, rising for three consecutive days on November 10, 2026
Moving higher for three straight days is viewed as a bullish sign. Keep an eye on this stock for future growth. Considering data from situations where LGVN advanced for three days, in 172 of 207 cases, the price rose further within the following month. The odds of a continued upward trend are 83%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The RSI Indicator points to a transition from a downward trend to an upward trend -- in cases where LGVN's RSI Indicator exited the oversold zone, 32 of 41 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 78%.
The Momentum Indicator moved above the 0 level on October 28, 2026. You may want to consider a long position or call options on LGVN as a result. In 78 of 95 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 82%.
Bearish Trend Analysis
The Stochastic Oscillator demonstrated that the ticker has stayed in the overbought zone for 8 days. The longer the ticker stays in the overbought zone, the sooner a price pull-back is expected.
The 50-day moving average for LGVN moved below the 200-day moving average on November 02, 2026. This could be a long-term bearish signal for the stock as the stock shifts to an downward trend.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where LGVN declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 90%.
LGVN broke above its upper Bollinger Band on November 09, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
The Aroon Indicator for LGVN entered a downward trend on October 28, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron Valuation Rating of 54 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (0.555) is normal, around the industry mean (3.498). P/E Ratio (-0.181) is within average values for comparable stocks, (-1.193). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (130.981) among similar stocks. P/S Ratio (13.587) is also within normal values, averaging (440.869).
The Tickeron Price Growth Rating for this company is 91 (best 1 - 100 worst), indicating slightly worse than average price growth. LGVN’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron PE Growth Rating for this company is 98 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron SMR rating for this company is 100 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. LGVN’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 93, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
Industry Biotechnology